Fatigue from cancer and its treatment is exhaustion that rest does not fix; for most people it improves after treatment ends, and physical activity, a regular sleep routine, eating well and planning the day around what matters most are the things shown to help.
Macmillan says "fatigue is a feeling of tiredness or exhaustion. Cancer and cancer treatments can cause fatigue" and that "for most people, fatigue gets better after treatment finishes. But for some it may continue for months or sometimes years". Causes it lists include the cancer itself, treatment, anaemia, eating problems and weight loss, pain, poor sleep and low mood. It advises that "physical activity, such as walking quickly, is one of the best ways to help reduce symptoms of fatigue", to "try to keep to a normal sleep routine", that "eating well and keeping to a healthy weight can help you maintain or regain your strength", and to plan the day "so that you have energy to do the things that are most important to you"; "it is important to tell a member of your healthcare team if you have fatigue at any time".
Cancer Research UK's bile duct cancer symptom page adds: "let your doctor or nurse know if you're very tired as they might be able to prescribe medicine to help", since treatable causes such as anaemia, low thyroid, infection or poor sleep are common. The site's records of exercise during chemotherapy and cognitive behavioural therapy for fatigue carry the trial evidence behind these tips. This is orientation from public patient pages, not advice for your case: your own team's instructions and 24-hour number come first.
Showing the technology this term belongs to: Cognitive behavioural therapy for fatigue and distress.
Shares Cardiopulmonary exercise testing: the hardest number in recovery, Exercise is the best-evidenced thing on this front, and most survivors are not doing it, Walking, gripping and standing up: the tests that take five minutes, Nodal marginal zone lymphoma.
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Relapsed and refractory classical Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Relapsed and refractory classical Hodgkin lymphoma.